Hoge der Aa.jpg

Program

Preliminary Program

Thursday November 10, 2022 

Pediatric Pulmonary Hypertension, A short introductory update course:

  • Diagnostic work up in 2022, the essentials

  • Current treatment strategies in 2022, the essentials

 

Molecular mechanisms of PAH, towards new therapies?

  • Pulmonary vascular remodeling, lessons to be learned from systemic atherosclerosis

  • The role of Inflammasome in the pathobiology of PAH

  • New PAH therapies to emerges: from pediatric trials and pre-clinical work

 

The new hemodynamic definition of PH: consequences for pediatric PH

  • Changing definition, changing disease? Panel discussion

 

Advanced intensive care for pediatric PAH

  • Lessons from a Potts-program

  • Lessons from a pediatric ECLS program

  • Lessons from a pediatric Lung transplant program

  • The role of ex-vivo perfusion in increasing donor lung availability

 

Case presentations

 

Down syndrome and PH in children

  • Clinical lung diseases in trisomy 21

  • Genetic aspects of pulmonary (vascular) disease in trisomy 21

  • PAH in children with versus without trisomy 21

Friday, November 11 2022

How to monitor your pediatric PAH patient

  • risk stratification and risk scores in pediatric PAH

  • Clinical value of new imaging techniques in monitoring pediatric PAH

  • When to assess your PH-patient: At rest or during exercise

 

New technologies in medicine, applicable in the pediatric PAH arena:

  • Nanomotors and photoregulation, borders to cross (preliminary Prof Feringa, Nobel prize winner Chemistry 2016)

  • The E-nose for diagnosing PAH using

  • Wearables and implantables in monitoring PH

  • Artificial Intelligence, applications in pediatric PAH

 

Neonatal pulmonary vascular disease

  • Diagnosing pulmonary hypertension in preterms: when and how?

  • Developmental lung disease”  how to move forward…?

  • PH and BPD

  • PH and CDH (Novel Approaches to Developmental Lung Diseases of the Pulmonary Vasculature)

  • Fetal growth restriction, pre-ecclampsia and neonatal pulmonary vascular disease, common vascular pathophysiology

  • Preventive treatment strategies for preterms at risk for developing BPD or late PH

 

Three Best Posters: Short oral communications

 

Deep phenotyping in pediatric PVD

  • Genetics, epi-genetics (Genotype-Phenotype relations in pediatric PAH)

  • Sex, sex hormones and ethnicity affecting RV and pulmonary vascular disease

  • Associated conditions and comorbidities in Pediatric PVD: cause, modifier or bystander

  • PVDOMICS-initiative and biomarkers: significance in pediatric PVD (provisional Allan Everett)

 

COVID-19 and PH in children

  • maternal COVID infection in the 3rd trimester of pregnancy increases the risk for PPHN

  • COVID-19 in pre-existing PAH

Social Program

Welcome dinner

On November 10 we will enjoy the conference dinner.

The dinner is included in the registration fee. 

Good-bye dinner

On November 11  there will be a Good-bye dinner, you can indicate during your registration if you want to join (price €50,00)

More info

For more information please contact us at info@gcb.nl